Adjustments to Total Assets
Adjustments to Current Liabilities
Adjustments to Total Liabilities
Adjustments to Stockholders’ Equity
Adjustments to Capitalization Table
Adjustments to Revenues
Adjustments to Reported Income

Moderna Inc., adjusted total assets

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Total assets	25,858)	24,669)	7,337)	1,589)	1,962)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	212)
Less: Deferred tax assets²	982)	326)	—)	—)	—)
After Adjustment
Adjusted total assets	24,876)	24,343)	7,337)	1,589)	2,174)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Deferred tax assets. See details »

Download chart

Moderna Inc., adjusted current liabilities

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Current liabilities	4,923)	9,128)	4,389)	143)	223)
Adjustments
Less: Deferred revenue, current	2,038)	6,253)	3,867)	63)	109)
After Adjustment
Adjusted current liabilities	2,885)	2,875)	522)	80)	114)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Download chart

Moderna Inc., adjusted total liabilities

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Total liabilities	6,735)	10,524)	4,775)	415)	432)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	212)
Less: Deferred revenue	2,711)	6,868)	4,045)	202)	274)
After Adjustment
Adjusted total liabilities	4,024)	3,656)	731)	212)	369)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

Download chart

Moderna Inc., adjusted stockholders’ equity

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Stockholders’ equity	19,123)	14,145)	2,561)	1,175)	1,530)
Adjustments
Less: Net deferred tax assets (liabilities)¹	982)	326)	—)	—)	—)
Add: Deferred revenue	2,711)	6,868)	4,045)	202)	274)
After Adjustment
Adjusted stockholders’ equity	20,852)	20,687)	6,606)	1,377)	1,805)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ Net deferred tax assets (liabilities). See details »

Download chart

Moderna Inc., adjusted capitalization table

US$ in millions

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Financing lease liabilities, current	161)	165)	24)	—)	—)
Financing lease liabilities, non-current	912)	599)	110)	39)	—)
Deferred lease obligation, non-current	—)	—)	—)	—)	10)
Lease financing obligation	—)	—)	—)	—)	33)
Total reported debt	1,073)	764)	134)	39)	43)
Stockholders’ equity	19,123)	14,145)	2,561)	1,175)	1,530)
Total reported capital	20,196)	14,909)	2,696)	1,213)	1,574)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	212)
Add: Operating lease liabilities, current²	35)	46)	6)	4)	—)
Add: Operating lease liabilities, non-current³	92)	106)	97)	94)	—)
Adjusted total debt	1,200)	916)	238)	136)	255)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	982)	326)	—)	—)	—)
Add: Deferred revenue	2,711)	6,868)	4,045)	202)	274)
Adjusted stockholders’ equity	20,852)	20,687)	6,606)	1,377)	1,805)
After Adjustment
Adjusted total capital	22,052)	21,603)	6,844)	1,513)	2,060)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Operating lease liabilities, current. See details »

³ Operating lease liabilities, non-current. See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

Moderna Inc., adjusted product sales

US$ in millions

12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Product sales	18,435)	17,675)	200)	—)	—)
Adjustment
Add: Increase (decrease) in deferred revenue	(4,157)	2,824)	3,842)	(72)	(65)
After Adjustment
Adjusted product sales	14,278)	20,499)	4,042)	(72)	(65)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Download chart

Moderna Inc., adjusted net income (loss)

US$ in millions

12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
As Reported
Net income (loss)	8,362)	12,202)	(747)	(514)	(385)
Adjustments
Add: Deferred income tax expense (benefit)¹	(578)	(296)	—)	(1)	—)
Add: Increase (decrease) in deferred revenue	(4,157)	2,824)	3,842)	(72)	(65)
Add: Other comprehensive income (loss), net of tax	(346)	(27)	1)	3)	—)
After Adjustment
Adjusted net income (loss)	3,281)	14,703)	3,096)	(584)	(450)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

¹ Deferred income tax expense (benefit). See details »

Download chart

Moderna Inc. (NASDAQ:MRNA)

Adjustments to Financial Statements

Adjustments to Total Assets

Adjustments to Current Liabilities

Adjustments to Total Liabilities

Adjustments to Stockholders’ Equity

Adjustments to Capitalization Table

Adjustments to Revenues

Adjustments to Reported Income